B.S. Merck could have built up almost a decade ago. They chose shortage and charging higher prices for a decade. They still may not be expanded until 2027.
Like any business decision NWBO choses a direction to follow based on circumstances and best available info about how those circumstances might change. The next Gen product does not help current patient need in the way Tice BCG would have at getting a previous Gen trial started while next Gen gets initial testing done. This also holds back business development which is an obvious attempt to keep relevance intact while keeping NWBO struggling. Can’t blame them for wanting to stay relevant but at some point the reality of what is coming will be apparent to all who are interested including the fact that cancer patients are and have been kept from potential cures due to business decisions and flipper44 is just pointing this out. Just like car makers deciding on payouts vs recall costs. Best wishes.
Market Data 
Markets 
AI
